| Literature DB >> 30205049 |
Lorenzo Brunetti1, Michael C Gundry2, Daniele Sorcini3, Anna G Guzman4, Yung-Hsin Huang5, Raghav Ramabadran6, Ilaria Gionfriddo3, Federica Mezzasoma3, Francesca Milano3, Behnam Nabet7, Dennis L Buckley8, Steven M Kornblau9, Charles Y Lin10, Paolo Sportoletti3, Maria Paola Martelli3, Brunangelo Falini3, Margaret A Goodell11.
Abstract
NPM1 is the most frequently mutated gene in cytogenetically normal acute myeloid leukemia (AML). In AML cells, NPM1 mutations result in abnormal cytoplasmic localization of the mutant protein (NPM1c); however, it is unknown whether NPM1c is required to maintain the leukemic state. Here, we show that loss of NPM1c from the cytoplasm, either through nuclear relocalization or targeted degradation, results in immediate downregulation of homeobox (HOX) genes followed by differentiation. Finally, we show that XPO1 inhibition relocalizes NPM1c to the nucleus, promotes differentiation of AML cells, and prolongs survival of Npm1-mutated leukemic mice. We describe an exquisite dependency of NPM1-mutant AML cells on NPM1c, providing the rationale for the use of nuclear export inhibitors in AML with mutated NPM1.Entities:
Keywords: AML; CRISPR; HOX; MEIS1; NPM1; XPO1; acute myeloid leukemia; dTAG; nuclear export; selinexor
Mesh:
Substances:
Year: 2018 PMID: 30205049 PMCID: PMC6159911 DOI: 10.1016/j.ccell.2018.08.005
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743